We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

ProBioGen and Lava Therapeutics Sign Development and Manufacturing Agreement for Novel Bispecific Molecule

Product News   Jan 15, 2020

 
ProBioGen and Lava Therapeutics Sign Development and Manufacturing Agreement for Novel Bispecific Molecule
FURTHER INFORMATION
 
 
 

Related Product News

Horizon Discovery and Mammoth Biosciences Collaborate To Improve Biotherapeutic Production

Product News

Horizon Discovery has signed a collaboration and license agreement with Mammoth Biosciences, to access Mammoth’s novel CRISPR platform and thereby facilitate delivery of a new generation of genetically engineered CHO cells for the production of biotherapeutics.

READ MORE

VivopureX™ Recombinant Antibodies for In Vivo Research

Product News

Absolute Antibody has announced the launch of its VivopureX™ recombinant mouse antibodies for in vivo research in mouse models.

READ MORE

Antibody Enters Clinical Trial for Treatment of B Cell Acute Lymphoblastic Leukemia

Product News

IONTAS has been informed that International Biotechnology Center (IBC) Generium has received approval from the Russian Health Authorities to initiate clinical trials with its CD3/CD19 bispecific antibody for the treatment of B Cell Acute Lymphoblastic Leukemia (ALL).

READ MORE

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE